Recommended Dosing for Daclatasvir and Sofosbuvir in Chronic Hepatitis C
The standard dose is sofosbuvir 400 mg once daily plus daclatasvir 60 mg once daily, taken orally without regard to food. 1
Treatment Duration Algorithm
The duration varies based on specific patient factors:
Non-Cirrhotic Patients
- 12 weeks of sofosbuvir 400 mg + daclatasvir 60 mg daily
- This applies across all HCV genotypes (1-6)
- SVR12 rates exceed 97% in this population 2
Cirrhotic Patients (Compensated)
- 24 weeks of sofosbuvir 400 mg + daclatasvir 60 mg daily
- The longer duration is critical: SVR12 rates are 95% with 24 weeks versus only 88% with 12 weeks in cirrhotic patients 2
- Consider adding ribavirin (weight-based: 1000-1200 mg daily) for genotype 3 cirrhosis, where it significantly improves outcomes (100% vs 40% SVR12) 3
Decompensated Cirrhosis
- 24 weeks of sofosbuvir 400 mg + daclatasvir 60 mg daily + ribavirin 600 mg daily
- This regimen achieved 82% SVR12 in genotype 1 with advanced cirrhosis 4
- Critical caveat: Patients with albumin <3.5 g/dL or MELD >14 have higher risk of further decompensation during therapy 5
Special Populations
Severe Renal Impairment (eGFR <30 mL/min) and Hemodialysis
While the FDA label states sofosbuvir safety is not established in severe renal impairment 1, real-world evidence strongly supports using standard doses without adjustment. A multicenter Iranian study of 103 patients (75 on hemodialysis) achieved 100% SVR12 with sofosbuvir 400 mg + daclatasvir 60 mg daily, with no treatment-related deaths or discontinuations 6. The 2020 EASL guidelines acknowledge sofosbuvir-based regimens can be used when other options are unavailable 7.
Post-Liver Transplant
- Standard doses: sofosbuvir 400 mg + daclatasvir 60 mg + ribavirin 600 mg daily for 12 weeks
- Achieved 95% SVR12 in transplant recipients 4
Administration Details
- Timing: Once daily dosing for both medications
- Food: Can be taken without regard to meals 1
- No dose adjustments needed for: age, gender, race, mild-moderate renal impairment, or any degree of hepatic impairment 1
Key Clinical Pitfalls
- Undertreating cirrhotic patients: The 12-week duration used in non-cirrhotics is insufficient for those with cirrhosis—always extend to 24 weeks
- Genotype 3 with cirrhosis: This is the most difficult-to-treat combination; ribavirin addition is essential 3
- Avoiding treatment in renal failure: Despite FDA labeling, strong real-world evidence supports safe use in ESRD 6
The combination demonstrates excellent safety profiles across all studies, with fatigue, headache, and nausea being the most common mild adverse events 8. No cardiac toxicity has been documented 9.